Clinical Trial Update: Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis [NA]

View source ↗

Summary

A clinical trial evaluating gecacitinib hydrochloride for prophylaxis of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Myelofibrosis

Drugs mentioned

• Gecacitinib hydrochloride (gecacitinib hydrochloride)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: aGVHD Prophylaxis | NA | Status: NOT_YET_RECRUITING